Day One Biopharmaceuticals to Participate at the 2021 Wedbush PacGrow Healthcare Virtual Conference
08/04/2021 - 08:00 AM
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers, today announced that Dr. Jeremy Bender, chief executive officer, is scheduled to participate in a panel discussion at the 12th Annual Wedbush PacGrow Healthcare Conference, which is being held virtually from August 10-11, 2021.
Panel Details: Title: “ Bullseye – Targeted Oncology Part 2”Date and time: Wednesday, August 11th , 10:20 a.m. ETPresenter: Jeremy Bender, Ph.D., MBA, Day One’s chief executive officerWebcast: https://ir.dayonebio.com/news-and-events/events
To access the live and archived webcasts, visit the News & Events section of the Company's website. A replay of the webcast will be available through the Company's website for 30 days thereafter.
About Day One Biopharmaceuticals Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers. Day One was founded to address a critical unmet need: children with cancer are being left behind in a cancer drug development revolution. Our name was inspired by the “The Day One Talk”1 that physicians have with patients and their families about an initial cancer diagnosis and treatment plan. We aim to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One.
Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important emerging cancer treatments. The Company’s lead product candidate, DAY101, is an oral, highly-selective type II pan-RAF kinase inhibitor, and is being evaluated in a pivotal Phase 2 clinical trial (FIREFLY-1) in pediatric, adolescent and young adult patients with recurrent or progressive low-grade glioma (pLGG). The Company’s pipeline also includes the investigational agent pimasertib, a clinical-stage, oral, small molecule found to selectively inhibit mitogen-activated protein kinase kinases 1 and 2 (MEK). Through Day One and its collaborators, cancer drug development comes of age. Day One is based in South San Francisco. For more information, please visit www.dayonebio.com .
1 Jennifer W. Mack and Holcombe E. Grier; Journal of Clinical Oncology 2004 22:3, 563-566
Contacts:
Media: 1AB Dan Budwickdan@1abmedia.com
Investors: LifeSci Advisors Hans Vitzthum 617-430-7578hans@lifesciadvisors.com
Day One Biopharmaceuticals Inc
DAWN Rankings
#4716 Ranked by Stock Gains
DAWN Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Country
US
City
San Francisco
About DAWN
day one biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. we are a unique company created to find and develop new therapies that meet the critical needs of people of all ages living with cancer – starting from the biology of childhood cancer. our distinctive approach, together with our trusted network of pediatric oncology investigators, gives us an unparalleled ability to advance promising discoveries for patients of any age. we are ready to pursue the full potential of our therapies to improve the greatest number of lives as quickly as possible.